ArticleThe clinical respiratory journal2012
Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.
Article in The clinical respiratory journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- One health approach to management of antifungal resistance in allergic bronchopulmonary aspergillosis.Molecular biology reports · 2026Review
- Provider Practices in Pulmonary Exacerbations of Cystic Fibrosis in the Era of Highly Effective Modulator Therapy.Annals of the American Thoracic Society · 2025Article
- The effect of modulators on lung function following inpatient treatment for CF exacerbations.Frontiers in pediatrics · 2025Article
- Mucus polymer concentration andmBio · 2024Article
- Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2021Review
- Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.Journal of personalized medicine · 2021Article
- Review
- Review
- Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2018Article
- Article
- Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice.British journal of pharmacology · 2017Article
- One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.Clinical medicine insights. Pediatrics · 2016Article
- Treatment of pulmonary exacerbations in cystic fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Cystic fibrosis chronic rhinosinusitis: a comprehensive review.American journal of rhinology & allergyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionCystic fibrosis (CF) pulmonary disease is characterized by intermittent episodes of acute lung symptoms known as 'pulmonary exacerbations'. While exacerbations are classically treated with parenteral antimicrobials, oral antibiotics are often used in 'mild' cases.
objectivesWe determined how often management progressed to intravenous (IV) therapy. We also examined multiple courses of oral antimicrobials within one exacerbation, and identified patient factors associated with unsuccessful treatment.
methodsWe performed a retrospective chart audit of oral antibiotic use in CF patients, from March 2009 through March 2010, for 'mild' CF exacerbations.
resultsAdministration of a single vs multiple courses of oral antibiotics for treatment of 'mild' CF exacerbation avoided progression to IV therapy 79.8% and 50.0% of the time, respectively. Overall, oral antibiotics circumvented the need for IV therapy 73.8% of the time. Using multi-variant analysis, we found multiple patient characteristics to be independent risk factors for oral antibiotic failure including a history of pseudomonas infection [odds ratio (OR) 2.13, confidence interval (CI) 1.29-3.54], CF-related diabetes (OR 1.85, CI 1.00-3.41), allergic Bronchopulmonary aspergillosis (OR 3.81, CI 1.38-10.56), low socioeconomic status (OR 1.67, CI 1.04-2.67), and calculated baseline forced expiratory volume in 1 s (FEV1) < 75% of predicted prior to an acute exacerbation (OR 1.93, CI 1.20-3.08). Decline in FEV1 > 10%, weight for age, body mass index, distance from the CF center and gender were not significant.
conclusionOur observations suggest that one course of oral antimicrobials is frequently effective in outpatient CF pulmonary exacerbations but exacerbations requiring more than one course of oral antibiotics are likely to require IV therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.